UNIVERSAL-PEACE-FED
5.8.2020 12:44:12 CEST | Business Wire | Press release
(Sunday August 9th, 3 am CET)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005488/en/
More than 1 Million are expected to join! World Leaders to point the way forward beyond global challenges including Covid-19, race relations, environmental problems and global economic turndown. Speakers include former UN Secretary-General Ban Ki-moon and H.E. Macky Sall, President of Senegal. UPF Co-Founder Dr. Hak Ja Han will offer a special keynote message of hope to humanity.
Registration link for online participants:
World Leaders to Address “Rally of Hope”
Despite material advances and the amassing of unprecedented wealth, serious global problems remain unsolved. This is all the more striking when it is seen alongside worldwide efforts to maintain peace, resolve conflicts and end poverty by major international peace-keeping bodies, public and private.
Territorial disputes, religious and racial discord, the collapse of family values, and an aggregate of environmental issues are flaring up on all continents. Added to this is the COVID-19 pandemic which has caused catastrophic economic debt. It seems like a perfect storm.
Just such dilemmas drew the late Rev. Dr. Sun Myung Moon and his wife Dr. Hak Ja Han Moon to speak out for the realization of an ideal world. Their vision: one human family bound together by the love of God. For decades, they have advocated the philosophy of interdependence, mutual prosperity, and universal values which challenges us with the novel concept of seeing our own purpose in life fulfilled in the well-being of others.
To emphasize these values and help address related problems, the Universal Peace Federation (an NGO in general consultative status with the Economic and Social Council of the United Nations), will be hosting the latest in a series of on-line virtual summits. The Rally of Hope will be held August 9, 2020 beginning at 9:40 AM (Korean time). The official theme is, “One Million Rally of Hope for the Realization of a Heavenly Unified World of Interdependence, Mutual Prosperity, and Universal Values.”
“The goal of these assemblies is to set a cornerstone for the realization of a world of proactive international and interreligious collaboration for the good of all people,” said Dr. Thomas G. Walsh, Chairman of the Universal Peace Federation.
Ban Ki-moon, former UN Secretary-General, will give the welcome address. Congratulatory messages presented by international dignitaries will follow. Interspersed with first-class entertainment, keynote addresses will be given by H.E. Hun Sen, Prime Minister of Cambodia; H.E. Macky Sall, President of Senegal; the Hon. Brigi Rafini, Prime Minister of Niger and other world leaders.
Finally, Dr. Hak Ja Han Moon, co-founder of the Universal Peace Federation and host of the Rally, will give her keynote address.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005488/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom